Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study
Buikhuisen, Wieneke A, MD, Burgers, Jacobus A, MD, Vincent, Andrew D, PhD, Korse, Catharina M, PhD, van Klaveren, Rob J, MD, Schramel, Franz MNH, MD, Pavlakis, Nick, Prof, Nowak, Anna K, Prof, Custers, Frank LJ, MD, Schouwink, J Hugo, MD, Gans, Steven JM, MD, Groen, Harry JM, Prof, Strankinga, Wim FM, MD, Baas, Paul, Prof
Published in The lancet oncology (01.05.2013)
Published in The lancet oncology (01.05.2013)
Get full text
Journal Article
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaieve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study
Scagliotti, Giorgio V, Park, Keunchil, Patil, Shekar, Rolski, Janusz, Goksel, Tuncay, Martins, Renato, Gans, Steven JM, Visseren-Grul, Carla, Peterson, Patrick
Published in European journal of cancer (1990) (01.09.2009)
Published in European journal of cancer (1990) (01.09.2009)
Get full text
Journal Article